Next 10 |
2024-05-10 07:27:16 ET More on Kronos Bio Kronos Bio: Underestimated Drug Discovery Platform Kronos cuts 21% of workforce, extends cash runway into 2H 2026 Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bio Finan...
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 —...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-05-06 18:40:11 ET Summary Kronos Bio, Inc.'s drug discovery platform has a lot of potential in targeting transcription regulatory networks. Genetech collaboration validates big pharma interest. KB-0742, Kronos Bio's lead asset, is an orally bioavailable highly selective CDK9 ...
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory t...
2024-03-21 13:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kronos Bio (NASDAQ: KRON ) just reported results for the fourth quarter of 2023. Kronos Bio reported earnings per share of -43 cents. This was above the analyst estimate f...
2024-03-21 12:41:20 ET More on Kronos Bio Kronos cuts 21% of workforce, extends cash runway into 2H 2026 Kronos Bio streamlines leadership, cuts CMO, CSO and COO roles Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bio ...
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-hum...
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
2024-03-07 16:37:27 ET More on Kronos Bio Kronos Bio streamlines leadership, cuts CMO, CSO and COO roles Kronos ends development of lanraplenib combo therapy for AML Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bio ...
News, Short Squeeze, Breakout and More Instantly...
Kronos Bio Inc. Company Name:
KRON Stock Symbol:
NASDAQ Market:
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 —...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming t...